Find the wacc and the unlevered cost of capital

Assignment Help Financial Management

Reference no: EM132018946

On Monday, January 26, 2009, Pfizer (NYSE: PFE), the world’s largest pharmaceuticals group, announced that over the weekend it had reached an agreement to acquire Wyeth (NYSE: WYE), one of the largest research-driven pharmaceutical and health care products companies. The deal would be the eighth-largest, M&A involving a US target, and the third largest globally in the pharma industry. Pfizer had been under pressure to re-invent itself, in particular because patents on several of its blockbuster drugs, currently generating a large fraction of the revenue, were due to expire in the coming years, meaning that revenues from sales of those drugs were expected to drop dramatically. Analysts argued that buying Wyeth would help Pfizer diversify its revenue sources and thus soften the expected blow to revenues and EPS from patent expiration. In addition, Wyeth’s expertise in vaccines would allow Pfizer to expand rapidly in biological medicines, a fast-growing, profitable niche in the industry that Pfizer had had little presence in. Finally, the merger would allow Pfizer to cut 15% of its global workforce, resulting in an expected reduction in operating costs totaling $4Bn over three years. Specifically, 50% of the cost savings would be realized by the end of year 1, 75% by the end of year 2, and 100% by the end of year 3. The deal would be financed with 2/3 equity and 1/3 debt. Assume that the risk-free rate is 1.67%, the market risk premium is 8.5% and the corporate tax rate is 34%. The following table reports some financial characteristics of Pfizer and Wyeth: Pfizer (NYSE: PFE) Wyeth (NYSE: WYE) Share price on Jan 16, 2009 17.13 38.54 No. of shares (Bn) 6.74 1.33 Total debt ($ Bn) 16.35 0 Equity beta 0.61 0.42 Cost of debt (%) 3.15% 4.81%

(a) Explain why the following are or are not good reasons for Pfizer to acquire Wyeth: (i) To diversify revenue sources in anticipation of patent expiry (ii) To gain entry into the biological medicine sector (iii) To cut costs by exploiting synergies

(b) Find the WACC and the unlevered cost of capital for both Pfizer and Wyeth as stand-alone firms pre-merger.

Reference no: EM132018946

Questions Cloud

Coupon bond paying coupons semiannually is callable : A 20-year maturity, 8% coupon bond paying coupons semiannually is callable in five years at a call price of $1,100.

What is the risk premium on factor : What is the risk premium on factor 2 if no arbitrage opportunities exist?

Standard deviation of the analyst profit : What is the expected profit (in dollars) and standard deviation of the analyst’s profit?

Disadvantages of using options to manage risk : What do you see as some of the important advantages and disadvantages of using options to manage risk?

Find the wacc and the unlevered cost of capital : Find the WACC and the unlevered cost of capital for both Pfizer and Wyeth as stand-alone firms pre-merger.

Write four-year guideline lease on the equipment : The equipment manufacturer informed Lewis that Consolidated Leasing would be willing to write a four-year guideline lease on the equipment.

Three alternatives for macrs three year property : Use the after-tax IRR (internal rate of return) method to evaluate the following three alternatives for a MACRS 3-year property,

What is the yield to maturity on the corporate bond : What is the yield to maturity on the corporate bond? What is the yield spread between this corporate bond and the risk free bond?

What ratio is a good indicator of large barriers to entry : what ratio is a good indicator of large barriers to entry?

User Account

All Pages